Reata Pharmaceuticals, Inc.
Symbol: RETA
NASDAQ
172.36
USDTržní cena dnes
-89.3629
Poměr P/E
0.0000
Poměr PEG
6.57B
MRK Cap
- 0.00%
Výnos DIV
Reata Pharmaceuticals, Inc. (RETA) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1474.56 | 387.5 | 590.3 | 818.1 | ||||||||||
balance-sheet.row.short-term-investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 16.95 | 0 | 0 | 22.2 | ||||||||||
balance-sheet.row.inventory | 8.65 | 0 | 0 | -22.2 | ||||||||||
balance-sheet.row.other-current-assets | 77.1 | 10.3 | 6.2 | 29.2 | ||||||||||
balance-sheet.row.total-current-assets | 1577.27 | 397.8 | 596.5 | 847.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 459.6 | 116.4 | 138.4 | 4.9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 17.44 | 0.3 | 0.2 | 5.3 | ||||||||||
balance-sheet.row.total-non-current-assets | 477.04 | 116.7 | 138.5 | 10.3 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 2054.3 | 514.5 | 735 | 857.6 | ||||||||||
balance-sheet.row.account-payables | 60.53 | 18.7 | 13.5 | 4.8 | ||||||||||
balance-sheet.row.short-term-debt | 13.07 | 2.2 | 3.1 | 87.5 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 534.25 | 117.3 | 136 | 0 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 4.7 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 131.23 | 38.1 | 35.7 | 22.3 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 1869.5 | 521.2 | 495 | 321 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 470.98 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.total-liab | 2158.86 | 580.2 | 549 | 440.2 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -6223.86 | -1567.5 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.18 | 1501.8 | 0 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 501.33 | 514.5 | -706.6 | -518.1 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 501.33 | - | - | - | ||||||||||
Total Investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 544.11 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.net-debt | 336.1 | 77.2 | -454.2 | -818.1 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -87.62 | -311.9 | -297.4 | -247.8 | ||||||||||
cash-flows.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
cash-flows.row.deferred-income-tax | -291.96 | 0 | 0 | 11.2 | ||||||||||
cash-flows.row.stock-based-compensation | 87.84 | 58.7 | 56.8 | 57.6 | ||||||||||
cash-flows.row.change-in-working-capital | 7.84 | 9.3 | -49.6 | -172.7 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | -13.28 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 11.97 | 5.2 | 8.7 | 2.9 | ||||||||||
cash-flows.row.other-working-capital | 9.16 | 4.1 | -58.3 | -175.6 | ||||||||||
cash-flows.row.other-non-cash-items | 34.44 | 38.5 | 53.3 | 28.1 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -248.34 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.acquisitions-net | 75 | 0 | 0 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -631.88 | -661.9 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 617.42 | 320 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 59.42 | -345.2 | -1.3 | -0.9 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -167.2 | ||||||||||
cash-flows.row.common-stock-issued | 222.73 | 0 | 333.3 | 333.3 | ||||||||||
cash-flows.row.common-stock-repurchased | 22.65 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -231.54 | 1.5 | -324.1 | 311 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 90.61 | 1.5 | 9.1 | 477.1 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 167.98 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -98.31 | -547.9 | -227.9 | 153.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 208.01 | 42.3 | 590.3 | 818.1 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 306.32 | 590.3 | 818.1 | 664.3 | ||||||||||
cash-flows.row.operating-cash-flow | -248.34 | -204.3 | -235.7 | -322.3 | ||||||||||
cash-flows.row.capital-expenditure | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.free-cash-flow | -249.46 | -207.5 | -237 | -323.3 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 24.39 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.cost-of-revenue | 0.85 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | 23.55 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 203.31 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 114.18 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.operating-expenses | 364.3 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 365.15 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.interest-income | 0 | 6 | 0.2 | 0 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.total-operating-expenses | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.ebitda-caps | -332.65 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -59.48 | -270.2 | -244.7 | -226.3 | ||||||||||
income-statement-row.row.income-before-tax | -87.68 | -311.9 | -297.8 | -270.2 | ||||||||||
income-statement-row.row.income-tax-expense | 0.25 | 0 | -0.5 | -22.5 | ||||||||||
income-statement-row.row.net-income | -80.06 | -311.9 | -297.4 | -247.8 |
Často kladené otázky
Co je Reata Pharmaceuticals, Inc. (RETA) celková aktiva?
Reata Pharmaceuticals, Inc. (RETA) celková aktiva jsou 514491000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 22941000.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.965.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -6.010.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je -3.282.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou -2.438.
Co je Reata Pharmaceuticals, Inc. (RETA) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je -311901000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 119464000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 280250000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 48843000.000.